Working with the NHS
At Bristol Myers Squibb, we recognise the significant challenges facing the NHS. The public rightly want fast access to high quality care at a time and place that is convenient to them.
At the same time, the global recession means budgets are increasingly constrained. The challenge for the NHS, therefore, is to meet these public expectations with tighter resources.
We believe our portfolio of existing and pipeline medicines can be part of the solution to these challenges. These new medicines will offer opportunities for the NHS to provide patients with better outcomes and better quality of life. Yet we also recognise that new treatments will present challenges to the NHS.
New medicines often increase the upfront cost of healthcare. They may also require staff training, new capacity or changes to patient pathways. At a time when resources are stretched it is ever more important that the NHS gets the most out of the new medicines it invests in, in terms of both clinical outcomes and patient experience.
In recognition of this, our approach at Bristol Myers Squibb is to work in partnership with the NHS to make sure it gets maximum value from our medicines.
Our teams are becoming more flexible when it comes to meeting customer needs rather than trying to apply a one-size-fits-all solution. In fact, we are now regularly having conversations with payers about providing a whole service and not just medicines.
Partnerships that bring value to the NHS
In order to meet its chosen strategy, every partnership entered into by Bristol Myers Squibb with the NHS must be underpinned by four key undertakings:
- Bristol Myers Squibb endeavours to continually develop medicines to meet true unmet medical need across a range of disease areas
- We are committed to enhancing clinical excellence through clinical research activities
- We will provide robust evidence on our medicines to support NHS decision makers
- Bristol Myers Squibb is striving to improve its service delivery so that its medicines reach the right patients at the right time.
|NHS Trust Name||Joint Working Project||Documents|
|Birmingham and Solihull Clinical Commissioning Group (BSOL CCG)||Reducing the number of avoidable Atrial Fibrillation (AF) related strokes across Birmingham and Solihull Clinical Commissioning Group||Summary of the Collaborative Working Agreement|
|Weston Park Cancer Centre (WPCC) part of the Sheffield Teaching Hospitals NHS Foundation Trust||Patient Experience Feedback Response to the Rapid Implementation of Virtual Clinics due to COVID-19||Outcomes Report|
|South Tees Hospital NHS Foundation Trust||Maximising the opportunity to detect, diagnose, and treat patients with obesity and atrial fibrillation [AF] through implementation of a multi-disciplinary (MDT) based integrated care pathway for local patients||Summary of the Collaborative Working Agreement|
|Academic Health Science Network for the North East and North Cumbria Limited||Reducing Atrial Fibrillation (AF) related strokes, through the design and implementation of service improvement initiatives across the Souther Collaborative||Summary of the Collaborative Working Agreement|
|Macmillan Cancer Support||Demonstrating the Value of Prehabilitation through Service and Workforce Efficiencies||Summary of the Collaborative Working Agreement|
|Tower Family Healthcare||Optimising the management of Atrial Fibrillation (AF) through a pharmacist-led approach, aligned to national policy which supports restoration and recovery of services through COVID-19 (C19)||Summary of Collaborative Working Agreement|
|Clatterbridge Cancer Centre NHS Foundation Trust||National Immuno-Oncology (IO) Clinical Network – bringing together IO Clinical Leaders as a National Clinical Network to champion and direct IO Service Development||Summary of Collaborative Working Agreement|
|Chelsea and Westminster NHS Foundation Trust||Optimising AF care for Hounslow Borough community within North West London Integrated Care System||Summary of Collaborative Working Agreement|
|Newcastle Upon Tyne Hospitals NHS Foundation Trust||Optimising future time to diagnosis for the Multiple Myeloma (MM) patient through understanding the current secondary care patient journey to inform a future exemplar pathway||Summary of Collaborative Working Agreement|
|Macmillan Cancer Support||Forecasting for innovation: A workforce planning tool||Summary of Collaborative Working Agreement|
Date of preparation: January 2023